Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50746 |
Name | mantle cell lymphoma |
Definition | A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma mantle cell lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
RB1 wild-type TP53 mut | R547 | mantle cell lymphoma | sensitive | detail... |
RB1 wild-type TP53 wild-type | R547 | mantle cell lymphoma | sensitive | detail... |
ATM inact mut | Olaparib | mantle cell lymphoma | sensitive | detail... |
ATM inact mut | Bendamustine + Olaparib | mantle cell lymphoma | sensitive | detail... |
ATM inact mut | Olaparib + Valproic acid | mantle cell lymphoma | sensitive | detail... |
ATM inact mut | Fludarabine + Olaparib | mantle cell lymphoma | sensitive | detail... |
TP53 loss | Bendamustine + Rituximab | mantle cell lymphoma | no benefit | detail... |
TP53 loss | Ibrutinib + Rituximab | mantle cell lymphoma | predicted - sensitive | detail... |
TP53 G244S | Ibrutinib + Rituximab | mantle cell lymphoma | predicted - sensitive | detail... |
ATM mutant | Ibrutinib + Venetoclax | mantle cell lymphoma | predicted - sensitive | detail... |
SMARCA4 mutant | Ibrutinib + Venetoclax | mantle cell lymphoma | predicted - resistant | detail... |
NRAS G13D | ERAS-007 | mantle cell lymphoma | sensitive | detail... |
NRAS G13D | Copanlisib + ERAS-007 | mantle cell lymphoma | sensitive | detail... |
ATM R2832C | RP-3500 | mantle cell lymphoma | sensitive | detail... |
ATM R2832C | Niraparib + RP-3500 | mantle cell lymphoma | sensitive | detail... |
ATM dec exp ATM inact mut | ART0380 | mantle cell lymphoma | predicted - sensitive | detail... |
TP53 mutant | N/A | mantle cell lymphoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00114738 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate Rituximab Bortezomib | EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma | Completed | USA | 0 |
NCT00602693 | Phase I | Sirolimus Allopurinol + Cyclophosphamide + Fludarabine | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | USA | 0 |
NCT00671112 | Phase I | Bortezomib + Everolimus | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT00878254 | Phase II | Cyclophosphamide + Cytarabine + Doxorubicin + Etoposide + Filgrastim + Ifosfamide + Leucovorin + Mesna + Methotrexate + Rituximab + Vincristine Sulfate Rituximab | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT01111188 | Phase I | Bortezomib + Palbociclib | Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma | Terminated | USA | 0 |
NCT01180049 | FDA approved | Temsirolimus | Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | Completed | USA | ROU | POL | ITA | FRA | DEU | CZE | AUS | 3 |
NCT01251575 | Phase II | Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus | Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | DNK | 0 |
NCT01267812 | Phase II | Bortezomib + Rituximab | Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation | Completed | USA | 0 |
NCT01415752 | Phase II | Bortezomib Bendamustine Rituximab Lenalidomide | Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma | Active, not recruiting | USA | CAN | 0 |
NCT01439750 | Phase Ib/II | Bortezomib + Cladribine + Rituximab | Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) | Unknown status | USA | 0 |
NCT01686165 | Phase II | Belinostat Rituximab | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01695941 | Phase I | Alisertib + Bortezomib + Rituximab | Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT01719250 | Phase I | Buparlisib | Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01796171 | Phase Ib/II | Lilotomab Betalutin Rituximab | A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) | Completed | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS | 2 |
NCT01799889 | Phase II | Entospletinib | A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies | Terminated | USA | CAN | 0 |
NCT01804686 | Phase III | Ibrutinib | A Long-term Extension Study of PCI-32765 (Ibrutinib) | Recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 10 |
NCT01811368 | Phase II | anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | Unknown status | USA | 0 |
NCT01880567 | Phase II | Ibrutinib + Rituximab | Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT01897012 | Phase I | Romidepsin Alisertib | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | Completed | USA | 0 |
NCT01905813 | Phase I | Dezapelisib + Itacitinib Dezapelisib | Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT01955499 | Phase I | Ibrutinib + Lenalidomide | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | CAN | 0 |
NCT01994382 | Phase I | Cerdulatinib | Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma | Completed | USA | 0 |
NCT02000934 | Phase I | Mivavotinib | A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies | Completed | USA | ITA | GBR | ESP | 0 |
NCT02018861 | Phase I | Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib | A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies | Completed | USA | 0 |
NCT02049541 | Phase I | Buparlisib + Rituximab | Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | Completed | USA | 0 |
NCT02106091 | Phase I | AFM11 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | Terminated | USA | POL | DEU | CZE | 0 |
NCT02159755 | Phase I | Ibrutinib + Palbociclib | Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02203903 | Phase I | MultiTAA-specific T cells | Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) | Recruiting | USA | 0 |
NCT02208037 | Phase II | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | Completed | USA | 0 | |
NCT02213926 | Phase II | Acalabrutinib | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | CZE | BEL | AUS | 0 |
NCT02242097 | Phase II | Ibrutinib | Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02268851 | Phase I | Ibrutinib + Umbralisib | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL | Completed | USA | 0 |
NCT02269085 | Phase Ib/II | Carfilzomib + Ibrutinib | A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma | Terminated | USA | 0 |
NCT02285244 | Phase II | Sotrastaurin | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation | Withdrawn | 0 | |
NCT02303392 | Phase I | Ibrutinib + Selinexor | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | Unknown status | USA | 0 |
NCT02328014 | Phase Ib/II | ACP-319 Acalabrutinib | ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT02339922 | Phase II | Ixazomib + Rituximab | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02381080 | Phase I | Erythromycin + Ibrutinib + Voriconazole | Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | Completed | ESP | CAN | 1 |
NCT02419560 | Phase I | Ibrutinib + Venetoclax | Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL | Completed | USA | 0 |
NCT02420795 | Phase Ib/II | ONC201 | Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT02427620 | Phase II | Cyclophosphamide + Doxorubicin + Vincristine Sulfate Filgrastim Dexamethasone Cytarabine + Methotrexate Leucovorin | A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02440685 | Phase Ib/II | ASN002 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Terminated | USA | ARG | 0 |
NCT02446236 | Phase I | Ibrutinib + Lenalidomide + Rituximab | Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Active, not recruiting | USA | 0 |
NCT02454270 | Phase II | JNJ-64052781 | A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies | Terminated | USA | ISR | FRA | ESP | BEL | 0 |
NCT02455297 | Phase II | Copanlisib | Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Terminated | USA | 0 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Terminated | USA | GBR | FRA | 0 |
NCT02489123 | Phase I | Enzalutamide | Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Terminated | USA | 0 |
NCT02564744 | Phase II | Naratuximab emtansine + Rituximab | Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL | Completed | USA | POL | ITA | HUN | CZE | CHE | BGR | BEL | 1 |
NCT02572453 | Phase II | Onalespib | Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) | Terminated | USA | 0 |
NCT02601313 | Phase II | axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) | Completed | USA | NLD | FRA | DEU | 0 |
NCT02603445 | Phase I | BCL201 + Idelalisib | Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL | Completed | USA | FRA | DEU | AUT | 0 |
NCT02631044 | Phase I | Lisocabtagene maraleucel | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | Completed | USA | 0 |
NCT02632396 | Phase Ib/II | Ixazomib + Rituximab | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | Active, not recruiting | USA | 0 |
NCT02650999 | Phase Ib/II | Pembrolizumab | Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas | Completed | USA | 0 |
NCT02706392 | Phase I | Cyclophosphamide + Fludarabine + ROR1 CAR-T cells | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Terminated | USA | 0 |
NCT02717624 | Phase I | Acalabrutinib + Bendamustine + Rituximab | A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma | Active, not recruiting | USA | POL | ITA | 0 |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Active, not recruiting | USA | 0 |
NCT02736617 | Phase II | Ibrutinib + Obinutuzumab | Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma | Completed | USA | 0 |
NCT02743546 | Phase I | Ibrutinib + JNJ-64052781 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma | Withdrawn | 0 | |
NCT02745769 | Phase I | Merestinib + Ramucirumab Abemaciclib + Ramucirumab | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | Completed | USA | GBR | FRA | 0 |
NCT02756247 | Phase I | Buparlisib + Ibrutinib | A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | Completed | USA | 0 |
NCT02776813 | Phase I | ACTR087 + Rituximab | Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma | Completed | USA | 0 |
NCT02797470 | Phase Ib/II | Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT02858258 | Phase III | Cisplatin + Cytarabine + Dexamethasone + Filgrastim + Rituximab Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | Recruiting | SWE | NOR | ITA | DNK | DEU | 0 |
NCT02869633 | Phase II | Ibrutinib | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT02875002 | Phase I | Belinostat + Volasertib | Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas | Withdrawn | USA | 0 |
NCT02900716 | Phase I | DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus | Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | Completed | USA | 0 |
NCT02931110 | Phase I | CBL0137 | Study of IV CBL0137 in Previously Treated Hematological Subjects | Terminated | USA | 0 |
NCT02950220 | Phase I | Ibrutinib + Pembrolizumab | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02972840 | Phase III | Bendamustine + Rituximab Acalabrutinib + Bendamustine + Rituximab | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | Active, not recruiting | USA | ROU | POL | NZL | ITA | ISR | HUN | GRC | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 10 |
NCT03010358 | Phase Ib/II | Entospletinib + Obinutuzumab | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT03015896 | Phase Ib/II | Lenalidomide + Nivolumab | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03019640 | Phase II | Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab | Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma | Completed | USA | 0 |
NCT03028103 | Phase I | Fluconazole + Tazemetostat Omeprazole + Repaglinide + Tazemetostat | Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects | Completed | USA | 0 |
NCT03037645 | Phase Ib/II | Vecabrutinib | Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers | Terminated | USA | 0 |
NCT03088878 | Phase Ib/II | Cirmtuzumab Cirmtuzumab + Ibrutinib Ibrutinib | A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | Completed | USA | 0 |
NCT03112174 | Phase III | Ibrutinib Ibrutinib + Venetoclax | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | Completed | USA | TUR | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 2 |
NCT03147885 | Phase Ib/II | Selinexor | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03153202 | Phase Ib/II | Ibrutinib + Pembrolizumab | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | Active, not recruiting | USA | 0 |
NCT03162536 | Phase I | ARQ 531 | Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03188965 | Phase I | Elimusertib | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | GBR | CHE | CAN | 3 |
NCT03189836 | Phase I | ACTR707 + Rituximab | Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma | Terminated | USA | 0 |
NCT03219047 | Phase I | Ibrutinib | The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response | Completed | USA | 0 |
NCT03232307 | Phase II | Ibrutinib + Lenalidomide + Rituximab | Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL) | Withdrawn | 0 | |
NCT03235544 | Phase II | Parsaclisib | A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) | Completed | USA | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CZE | BEL | 0 |
NCT03267433 | Phase III | Rituximab | Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | Active, not recruiting | USA | 1 |
NCT03277729 | Phase Ib/II | CD20 CAR-T cells + Cyclophosphamide + Fludarabine | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT03282396 | Phase II | Ibrutinib | Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03311126 | Phase II | Bendamustine + Obinutuzumab | Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma | Terminated | USA | 0 |
NCT03323151 | Phase Ib/II | Ibrutinib + Ixazomib | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma (PrE0404) | Completed | USA | 0 |
NCT03379493 | Phase I | Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | Terminated | USA | 0 | |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03424122 | Phase I | Ibrutinib + Parsaclisib Bendamustine + Parsaclisib + Rituximab Parsaclisib + Rituximab | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | Completed | USA | ITA | ESP | 0 |
NCT03424603 | Phase I | STRO-001 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | Completed | USA | 0 |
NCT03440567 | Phase I | Avelumab + Carboplatin + Etoposide + Ifosfamide + Rituximab + Utomilumab Avelumab + Ibrutinib + Rituximab + Utomilumab | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03478514 | Phase II | Ibrutinib + Palbociclib | Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03479268 | Phase I | Ibrutinib + MLN4924 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03523975 | Phase I | Lenalidomide + Rituximab + Venetoclax | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT03537482 | Phase I | APG-2575 | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT03547115 | Phase I | Voruciclib | A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies | Recruiting | USA | 0 |
NCT03557619 | Phase I | Ethinylestradiol + Levonorgestrel + Venetoclax | A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies | Recruiting | USA | AUS | 0 |
NCT03571568 | Phase Ib/II | BI-1206 + Rituximab | A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | SWE | POL | ESP | DEU | BRA | 0 |
NCT03571828 | Phase I | AMG562 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma | Terminated | USA | DEU | CAN | BEL | 0 |
NCT03579927 | Phase Ib/II | Filgrastim iC9-CAR.19-IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | Withdrawn | USA | 0 |
NCT03585725 | Phase I | Ribavirin | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma | Terminated | USA | 0 |
NCT03601819 | Phase I | Pacritinib | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Terminated | USA | 0 |
NCT03617484 | Phase II | Bortezomib + Ibrutinib | Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma | Withdrawn | USA | 0 |
NCT03623373 | Phase II | Acalabrutinib + Bendamustine + Cytarabine + Rituximab | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03625037 | Phase Ib/II | Epcoritamab-bysp | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1) | Active, not recruiting | USA | SWE | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUS | 2 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT03682796 | Phase I | TRPH-222 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | Completed | USA | CAN | 0 |
NCT03684694 | Phase I | Ibrutinib + Loncastuximab tesirine-lpyl | Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | Terminated | USA | ITA | GBR | FRA | ESP | BEL | 0 |
NCT03685344 | Phase I | Durvalumab + Loncastuximab tesirine-lpyl | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | Terminated | USA | ESP | 0 |
NCT03696784 | Phase I | Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Recruiting | USA | 0 |
NCT03710772 | Phase II | Ibrutinib + Rituximab + Venetoclax Cyclophosphamide + Dexamethasone + Doxorubicin + Rituximab + Vincristine Sulfate Cytarabine + Methotrexate + Rituximab | Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03740529 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Active, not recruiting | USA | SWE | POL | ITA | GBR | FRA | CHE | AUS | 2 |
NCT03755154 | Phase I | VOB560 | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia | Terminated | GBR | FRA | ESP | AUS | 0 |
NCT03765177 | Phase Ib/II | CLIC-1901 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01) | Recruiting | CAN | 0 |
NCT03779113 | Phase Ib/II | HMPL-523 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | Active, not recruiting | USA | POL | ITA | FRA | FIN | ESP | DNK | 0 |
NCT03786926 | Phase Ib/II | HMPL-689 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | Active, not recruiting | USA | POL | ITA | FRA | FIN | ESP | 0 |
NCT03833180 | Phase I | VLS-101 | A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies | Completed | USA | 0 |
NCT03834688 | Phase II | Bendamustine + Rituximab + Venetoclax | Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (PrE0405) | Completed | USA | 0 |
NCT03863184 | Phase II | Acalabrutinib + Lenalidomide + Rituximab | Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | Active, not recruiting | USA | 0 |
NCT03872180 | Phase II | Bendamustine + Obinutuzumab + Venetoclax | Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03877055 | Phase Ib/II | Copanlisib + Ibrutinib Ibrutinib | A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma | Completed | USA | 0 |
NCT03886831 | Phase I | PRT543 | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies | Completed | USA | 0 |
NCT03920631 | Phase I | Nivolumab | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) | Withdrawn | USA | 0 |
NCT03939182 | Phase Ib/II | Abexinostat + Ibrutinib | Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03946878 | Phase II | Acalabrutinib + Venetoclax | Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04002297 | Phase III | Rituximab + Zanubrutinib Bendamustine + Rituximab | Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Patients With Untreated Mantle Cell Lymphoma | Active, not recruiting | USA | TUR | ROU | POL | NZL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 6 |
NCT04007029 | Phase I | Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04014205 | Phase I | Orelabrutinib | A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies | Active, not recruiting | USA | POL | ISR | 1 |
NCT04043845 | Phase I | Ibrutinib + LY3214996 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Withdrawn | 0 | |
NCT04047797 | Phase II | Ixazomib + Rituximab | Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04052854 | Expanded access | Zanubrutinib | A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Patients With B-cell Malignancies | No longer available | USA | 0 |
NCT04072458 | Phase I | BP1002 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Recruiting | USA | 0 |
NCT04074330 | Phase Ib/II | Rituximab + Subasumstat | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | 2 |
NCT04082936 | Phase I | IGM-2323 | A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | Terminated | USA | ITA | FRA | ESP | CZE | AUS | 1 |
NCT04115631 | Phase II | Acalabrutinib + Bendamustine + Rituximab Bendamustine + Cytarabine + Rituximab Acalabrutinib + Bendamustine + Cytarabine + Rituximab | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04136275 | Phase I | Anti-CD37 CAR T cells | CAR-37 T Cells In Hematologic Malignancies | Completed | USA | 0 |
NCT04160195 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | Terminated | USA | 0 |
NCT04162756 | Expanded access | Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine | Study of KTE-X19 for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies (ZUMA-18) | Approved for marketing | USA | 0 |
NCT04189757 | Phase II | Acalabrutinib | Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04223765 | Phase I | Bendamustine + CAR.k.28 cells + Fludarabine CAR.k.28 cells + Cyclophosphamide + Fludarabine | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04277637 | Phase I | BGB-11417 + Zanubrutinib BGB-11417 | Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | Recruiting | USA | NZL | ITA | GBR | ESP | DEU | AUS | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04283097 | Phase I | KPG-818 | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | Recruiting | USA | 0 |
NCT04401020 | Phase I | SAR442257 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | Active, not recruiting | USA | NOR | ESP | CZE | 1 |
NCT04402138 | Phase II | Acalabrutinib | Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | Completed | USA | 0 |
NCT04419389 | Phase Ib/II | Acalabrutinib + APR-246 APR-246 + Rituximab + Venetoclax | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | Terminated | USA | 0 |
NCT04484012 | Phase II | Acalabrutinib + CD19R(EQ)28zetaEGFRt+ Tn/mem cells | Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT04491370 | Phase Ib/II | Polatuzumab vedotin-piiq | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04540796 | Phase I | JNJ-75348780 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | ISR | GBR | FRA | ESP | AUS | 2 |
NCT04545762 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04566887 | Phase II | Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma | Active, not recruiting | CAN | 0 |
NCT04578600 | Phase I | Azacitidine + Lenalidomide + Obinutuzumab | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04594642 | Phase I | TNB-486 | A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | AUS | 3 |
NCT04599634 | Phase I | Hu5F9-G4 + Obinutuzumab + Venetoclax | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | Completed | USA | 0 |
NCT04626791 | Phase II | Acalabrutinib + Cytarabine + Rituximab Hyaluronidase Acalabrutinib + Cytarabine + Rituximab Acalabrutinib + Bortezomib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Acalabrutinib + Bortezomib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Hyaluronidase | Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT04635683 | Phase I | Lenalidomide + Ublituximab + Umbralisib | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | Withdrawn | 0 | |
NCT04640779 | Phase I | Choline salicylate + Selinexor | Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Residual, Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04659044 | Phase II | Polatuzumab vedotin-piiq + Rituximab + Rituximab Hyaluronidase + Venetoclax Rituximab Hyaluronidase + Venetoclax | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Terminated | USA | 0 |
NCT04662255 | Phase III | Ibrutinib Zanubrutinib Pirtobrutinib Acalabrutinib | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321) | Active, not recruiting | USA | POL | NZL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 6 |
NCT04665115 | Phase II | Ibrutinib | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | Withdrawn | USA | 0 |
NCT04684563 | Phase I | HuCART19-IL18 | huCART19-IL18 in NHL/CLL Patients | Recruiting | USA | 0 |
NCT04692155 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Prednisone + Ublituximab + Umbralisib + Vincristine Sulfate | Phase Ib/II Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) (CHOP U2) | Terminated | USA | 0 |
NCT04703686 | Phase II | Glofitamab-gxbm + Obinutuzumab | Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | Active, not recruiting | FRA | 0 |
NCT04728893 | Phase II | ARQ 531 | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | Recruiting | USA | TUR | ROU | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUS | ARG | 3 |
NCT04763083 | Phase Ib/II | NVG-111 | First in Human Study of NVG-111 in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma | Recruiting | GBR | 0 |
NCT04765111 | Phase II | Acalabrutinib + Rituximab | Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04783415 | Phase II | Acalabrutinib + Ublituximab + Umbralisib | Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04802590 | Phase II | Ibrutinib Ibrutinib + Venetoclax | Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | Recruiting | GBR | FRA | BEL | 0 |
NCT04809467 | Phase Ib/II | Parsaclisib + Tafasitamab-cxix | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) | Completed | USA | ITA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT04830137 | Phase I | NX-2127 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | 0 |
NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Recruiting | CAN | 0 |
NCT04842877 | Phase II | DS-3201b | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma | Active, not recruiting | FRA | BEL | 0 |
NCT04853329 | Phase Ib/II | CPO107 | Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma | Suspended | USA | 0 |
NCT04855695 | Phase Ib/II | Acalabrutinib + Obinutuzumab + Venetoclax | Avo In R/R And Previously Untreated MCL | Recruiting | USA | 0 |
NCT04861779 | Phase I | HSK29116 | A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies | Unknown status | AUS | 1 |
NCT04880434 | Phase II | Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine | Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) | Active, not recruiting | USA | NLD | GBR | FRA | ESP | DEU | 0 |
NCT04883437 | Phase II | Acalabrutinib + Obinutuzumab | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | Recruiting | USA | 0 |
NCT04903197 | Phase I | Lenalidomide + VAY736 VAY736 | Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | Active, not recruiting | ITA | DEU | AUS | 4 |
NCT04913103 | Phase II | Bendamustine + Polatuzumab vedotin-piiq + Rituximab | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL (CLSGMCLPOLA) | Not yet recruiting | CZE | 0 |
NCT04939272 | Phase Ib/II | Copanlisib + Venetoclax | Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04975555 | Phase II | Siltuximab | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | Recruiting | USA | 0 |
NCT04990778 | Phase II | APR-246 + Venetoclax | Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma | Withdrawn | USA | 0 |
NCT05003141 | Phase I | PSB202 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | Unknown status | USA | AUS | 1 |
NCT05006716 | Phase I | BGB-16673 | A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies | Recruiting | USA | TUR | SWE | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 3 |
NCT05008055 | Phase II | Capivasertib | Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL) | Active, not recruiting | USA | GBR | FRA | ESP | DNK | CAN | 1 |
NCT05020678 | Phase I | Cyclophosphamide + Fludarabine NKX019 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Recruiting | USA | AUS | 0 |
NCT05025423 | Phase II | Rituximab + Venetoclax | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT05025800 | Phase Ib/II | Evorpacept + Lenalidomide + Rituximab | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05053659 | Phase I | Loncastuximab tesirine-lpyl + Venetoclax | Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05065866 | Phase I | Azacitidine + Duvelisib | Duvelisib in Combination With CC-486 in Lymphoid Malignancy | Active, not recruiting | USA | 0 |
NCT05131022 | Phase I | NX-5948 | Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | NLD | GBR | 0 |
NCT05144347 | Phase I | XL114 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT05172700 | Expanded access | Pirtobrutinib | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | Available | 0 | |
NCT05205161 | Phase Ib/II | AZD0466 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | Terminated | USA | ITA | FRA | ESP | AUS | 2 |
NCT05205252 | Phase Ib/II | Lenalidomide + Tafasitamab-cxix + Tazemetostat Daratumumab + Dexamethasone + Pomalidomide + Tazemetostat Daratumumab and hyaluronidase-fihj + Dexamethasone + Pomalidomide + Tazemetostat Mosunetuzumab-axgb + Tazemetostat Lenalidomide + Tazemetostat Acalabrutinib + Tazemetostat | A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. (ARIA) | Withdrawn | USA | 0 |
NCT05207670 | Phase II | Mosunetuzumab-axgb + Tocilizumab | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) | Active, not recruiting | USA | 0 |
NCT05211336 | Phase I | Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax | Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | Active, not recruiting | USA | 0 |
NCT05249959 | Phase II | Bendamustine + Cytarabine + Rituximab Loncastuximab tesirine-lpyl | Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (FIL_COLUMN) | Recruiting | ITA | 0 |
NCT05260957 | Phase II | Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | Recruiting | USA | 0 |
NCT05279300 | Phase I | CS5001 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | AUS | 1 |
NCT05346809 | Phase II | Isatuximab | Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | Recruiting | USA | 0 |
NCT05348889 | Phase Ib/II | 1A46 | First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT05360238 | Phase Ib/II | MB-106 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | Terminated | USA | 0 |
NCT05365659 | Phase I | IKS03 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | Recruiting | USA | ITA | ESP | CAN | AUS | 0 |
NCT05370430 | Phase I | BAFFR-CAR T cells | BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL | Recruiting | USA | 0 |
NCT05424822 | Phase I | JNJ-80948543 | A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | POL | ISR | FRA | DNK | AUS | 2 |
NCT05458297 | Phase II | VLS-101 ARQ 531 + VLS-101 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination With Nemtabrutinib (MK-1026) in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | Recruiting | USA | TUR | SWE | POL | ITA | ISR | IRL | GBR | EST | ESP | DEU | CZE | CAN | BRA | 7 |
NCT05471843 | Phase II | BGB-11417 | Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | Active, not recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | BRA | BEL | ARG | 2 |
NCT05495464 | Phase I | Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT05529069 | Phase II | Pirtobrutinib + Venetoclax | Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients | Recruiting | USA | 0 |
NCT05564052 | Phase II | Ibrutinib + Rituximab Bortezomib + Lenalidomide + Rituximab | A Study of Ibrutinib With Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (VEGA) | Completed | TUR | SWE | ROU | POL | GRC | ESP | CZE | BRA | 5 |
NCT05588440 | Phase Ib/II | Cyclophosphamide + Fludarabine ONCT-808 | A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies | Terminated | USA | 0 |
NCT05602363 | Phase I | AS-1763 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05635162 | Phase II | Rituximab + Zanubrutinib | Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma (ZEBRA) | Recruiting | GBR | 0 |
NCT05659732 | Phase I | PEP07 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | Recruiting | AUS | 1 |
NCT05665530 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | POL | ITA | GBR | FRA | DEU | CHE | CAN | AUS | 1 |
NCT05702853 | Phase Ib/II | CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | Recruiting | USA | 0 |
NCT05753501 | Phase I | ABBV-101 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | CAN | 1 |
NCT05773040 | Phase I | JV-213 | A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | Active, not recruiting | USA | 0 |
NCT05780034 | Phase I | AC0676 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Recruiting | USA | 0 |
NCT05788289 | Phase II | Lenalidomide + Tafasitamab-cxix | A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma | Terminated | USA | 0 |
NCT05797233 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT05798897 | Phase I | MT-601 | Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO) | Recruiting | USA | 0 |
NCT05801913 | Phase I | CMV-CD19 CAR T-cells + Multi-antigen CMV-modified vaccinia Ankara vaccine | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05833763 | Phase II | Glofitamab-gxbm Glofitamab-gxbm + Pirtobrutinib Obinutuzumab | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. (GOlDiLOX) | Recruiting | AUS | 0 |
NCT05861050 | Phase Ib/II | Glofitamab-gxbm + Lenalidomide + Obinutuzumab + Venetoclax | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT05864742 | Phase II | Ibrutinib + Rituximab + Venetoclax Ibrutinib + Navitoclax + Rituximab + Venetoclax | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (+/-Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma | Active, not recruiting | AUS | 0 |
NCT05868395 | Phase II | Bendamustine + Polatuzumab vedotin-piiq + Rituximab | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma | Recruiting | AUT | 0 |
NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Active, not recruiting | USA | AUS | 0 |
NCT05879744 | Phase I | CLN-978 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | Active, not recruiting | USA | 0 |
NCT05910801 | Phase II | Lenalidomide + Tafasitamab-cxix + Venetoclax | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (V-MIND) | Recruiting | USA | 0 |
NCT05934838 | Phase I | Tazemetostat | A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | Recruiting | USA | 0 |
NCT05950165 | Phase Ib/II | CHO-H01 + Lenalidomide CHO-H01 | A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | Recruiting | USA | 1 |
NCT05951959 | Phase II | Acalabrutinib + Rituximab + Venetoclax | A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse) | Active, not recruiting | USA | POL | GBR | ESP | CAN | BRA | AUS | 0 |
NCT05967416 | Phase I | SIRPant-M | Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT05976763 | Phase III | Zanubrutinib Rituximab + Zanubrutinib | Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT05989204 | Phase I | HuCART19-IL18 | TmCD19-IL18 in CD19+ Cancers | Recruiting | USA | 0 |
NCT06014762 | Phase I | P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Recruiting | USA | 0 |
NCT06026319 | Phase I | CD79b-19 CAR T cells Cyclophosphamide + Fludarabine | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT06029309 | Phase Ib/II | Tafasitamab-cxix + Zanubrutinib | Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma (ZANU-TAFA) | Recruiting | USA | 0 |
NCT06054776 | Phase II | Acalabrutinib + Glofitamab-gxbm + Obinutuzumab | Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT06084936 | Phase III | Obinutuzumab Glofitamab-gxbm Lenalidomide + Rituximab Bendamustine + Rituximab | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE) | Recruiting | USA | SWE | ITA | GBR | FRA | ESP | CAN | BRA | AUS | 3 |
NCT06088654 | Phase Ib/II | IPH6501 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | FRA | AUS | 0 |
NCT06132503 | Phase I | LP-284 | A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors | Recruiting | USA | 0 |
NCT06191887 | Phase I | Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT06192888 | Phase I | Glofitamab-gxbm + Lenalidomide + Obinutuzumab | A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT06208735 | Phase I | CLIC-2201 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | Not yet recruiting | CAN | 0 |
NCT06252675 | Phase II | Glofitamab-gxbm + Obinutuzumab + Pirtobrutinib | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | Suspended | USA | 0 |
NCT06256484 | Phase I | ATA3219 | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | AUS | 0 |
NCT06263491 | Phase II | Pirtobrutinib + Rituximab Rituximab | Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients | Recruiting | USA | 0 |
NCT06285422 | Phase I | Cyclophosphamide + Fludarabine SC262 | Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | Recruiting | USA | 0 |
NCT06300528 | Phase II | Pemigatinib | Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma | Not yet recruiting | USA | 0 |
NCT06340737 | Phase I | Anti-CD22 CAR T cells | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | Recruiting | USA | 0 |
NCT06343311 | Phase Ib/II | EB103 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1) | Recruiting | USA | 0 |
NCT06343376 | Phase I | EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT06357676 | Phase Ib/II | Glofitamab-gxbm + Ibrutinib + Obinutuzumab | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma | Not yet recruiting | USA | 0 |
NCT06378190 | Phase Ib/II | TranspoCART19 | Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19) | Recruiting | ESP | 0 |
NCT06392477 | Phase I | DR-0201 | A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | AUS | 5 |
NCT06482684 | Phase II | Ibrutinib Ibrutinib + Rituximab Bendamustine + Ibrutinib + Rituximab Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Brexucabtagene autoleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab | CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma (CARMAN) | Recruiting | DEU | 0 |
NCT06484920 | Phase II | Pembrolizumab + Tretinoin | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL | Recruiting | USA | 0 |
NCT06492304 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT06522386 | Phase II | Pirtobrutinib + Rituximab + Venetoclax | GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma | Not yet recruiting | USA | 0 |
NCT06542250 | Phase Ib/II | AZD5492 | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. (TITANium) | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | CAN | AUS | 2 |
NCT06553872 | Phase II | Brexucabtagene autoleucel Brexucabtagene autoleucel + Pirtobrutinib Pirtobrutinib | Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL | Recruiting | USA | 0 |
NCT06558604 | Phase II | Glofitamab-gxbm + Obinutuzumab + Venetoclax + Zanubrutinib Glofitamab-gxbm + Obinutuzumab + Venetoclax | A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma (GLOASIS) | Not yet recruiting | FRA | BEL | 0 |
NCT06561425 | Phase Ib/II | GLPG5101 | A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma (Atalanta-1) | Recruiting | USA | NLD | BEL | 0 |
NCT06572618 | Phase II | ARQ 531 + Rituximab | Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma | Not yet recruiting | USA | 0 |
NCT06675123 | Phase I | Acalabrutinib + Pacritinib Pacritinib + Zanubrutinib Ibrutinib + Pacritinib | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | Not yet recruiting | USA | 0 |